Trial reportJournal of bone and mineral metabolism2018
Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.
Trial report in Journal of bone and mineral metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data.Frontiers in immunology · 2021Pooled it
- Research progress on complications of rheumatoid arthritis.Frontiers in immunology · 2025Review
- Effects of Locomotion Training on Bone Mineral Density in Patients with Rheumatoid Arthritis.Progress in rehabilitation medicine · 2024Article
- The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients.Inflammopharmacology · 2023Review
- Machine learning to characterize bone biomarkers profile in rheumatoid arthritis.Frontiers in immunology · 2023Article
- Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis.Journal of clinical medicine · 2022Review
- Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study.Osteoporosis and sarcopenia · 2021Article
- Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies.Journal of orthopaedic surgery and research · 2021Article
- Therapeutic efficacy of denosumab for rheumatoid arthritis: a systematic review and meta-analysis.Rheumatology advances in practice · 2021Article
- RANKL as a therapeutic target of rheumatoid arthritis.Journal of bone and mineral metabolism · 2021Review
- Targeting the RANKL/RANK/OPG Axis for Cancer Therapy.Frontiers in oncology · 2020Review
- Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study.Nagoya journal of medical science · 2019Article
- Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database.Therapeutics and clinical risk management · 2019Article
- Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice.Nutrients · 2018Article
- Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis.Therapeutics and clinical risk management · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to investigate the efficacy of denosumab for rheumatoid arthritis (RA). This study enrolled 70 RA patients who received denosumab 60 mg subcutaneous injection at baseline and at 6 months. Bone mineral densities (BMD) of the lumbar spine, total hip, femoral neck, and hand were measured by dual energy X-ray absorptiometry. Changes in total modified Sharp score (mTSS), erosion (EN) score, and joint space narrowing score at baseline from 12 months before and at 12 months from baseline. The mean values of BMD of the lumbar spine, total hip, femoral neck, and hand significantly increased by 7.3, 4.7, 3.9, and 5.4%, respectively, at 12 months. At 12 months from baseline, there were significant decreases in the values of mTSS (1.13 vs. 0.59; p = 0.002) and EN score (0.40 vs. 0.07; p < 0.001), compared with the values at baseline from 12 months before. The existing combined modality therapy with denosumab might be effective for osteoporosis and joint destruction in patients with RA.
Indexed as
Identifiers
28681148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.